About Horizon Pharma PLC
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units. Its segment focuses on the identification, development, acquisition and commercialization of differentiated and accessible medicines. Its marketed medicines include ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate and caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% w/w, or PENNSAID 2%, RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). It also developed DUEXIS and RAYOS, known as LODOTRA.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: Pharmaceuticals
- Exchange: NASDAQ
- Symbol: HZNP
- CUSIP: 44047T10
- Previous Close: $17.15
- 50 Day Moving Average: $16.84
- 200 Day Moving Average: $18.29
- 52-Week Range: $161,257,000.00 - $13.05
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 7.36
- P/E Growth: 0.47
- Market Cap: $2.81B
- Outstanding Shares: 161,257,000
- Beta: 1.76
- Net Margins: -1.34%
- Return on Equity: 22.73%
- Return on Assets: 9.38%
Companies Related to Horizon Pharma PLC:
- Debt-to-Equity Ratio: 0.84%
- Current Ratio: 2.01%
- Quick Ratio: 1.72%
What is Horizon Pharma PLC's stock symbol?
Horizon Pharma PLC trades on the NASDAQ under the ticker symbol "HZNP."
Where is Horizon Pharma PLC's stock going? Where will Horizon Pharma PLC's stock price be in 2017?
11 brokerages have issued 1-year target prices for Horizon Pharma PLC's stock. Their forecasts range from $21.00 to $45.00. On average, they expect Horizon Pharma PLC's share price to reach $29.82 in the next twelve months.
When will Horizon Pharma PLC announce their earnings?
Horizon Pharma PLC is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
What are analysts saying about Horizon Pharma PLC stock?
Here are some recent quotes from research analysts about Horizon Pharma PLC stock:
- Mizuho analysts commented, "We are positive on HZNP ahead of the February 27 earnings call: We think the company may deliver a 4Q:16 earnings beat. We model 4Q:16 revenues of $325.4M and EPS of $0.57 relative to consensus $308.5M and $0.50 and implied guidance $309-$314M. Horizon has delivered strong beats in the past and we expect adjusted EBITDA to approach the higher end of the guidance range of $450-$460M. With respect to 2017 guidance, we fall below FactSet consensus estimates of $1,289.7M and $2.39 (we model $1,281.8M and $2.29), but note that Horizon may be able to beat this range via a combination of both price and volume growth, so guidance could come in stronger than expected. There is still significant uncertainty around business operation under the new PBM contracts, gross to net discounts, infrastructure needs, and the timing of anticipated volume growth. We therefore expect the focus of the call to be around these issues as well as on future business development targets and pipeline outlook." (2/22/2017)
According to Zacks Investment Research, "Horizon’s growth-by-acquisition strategy, through which it actively pursues deals to expand and diversify its portfolio, is encouraging. The Raptor Pharma acquisition to strengthen its rare disease business is impressive. Moreover, the Hyperion and Crealta acquisitions bode well. However, the company’s efforts to expand Actimmune’s label suffered a developmental setback. Actimmune failed in a late-stage Friedreich's ataxia study, which could have given its sales a much-needed boost. Horizon is also involved in patent litigations with quite a few companies. Also, Horizon’s marketed products face intense competition. Pipeline setbacks, competitive pressures, concerns related to the ongoing litigations and focus on drug pricing remain material headwinds. The company has a negative record of earnings surprise in the last four trailing quarters while the estimates are stable ahead of Q4 results." (2/17/2017)
Jefferies Group LLC analysts commented, "Q2 results were well ahead of consensus (revs +10%, EPS +11%), driven by stronger revs from primary care products (+$19M vs JEF). This outperformance came despite higher than forecasted expenses (+$7M vs JEF). Mgt also reaffirmed its FY16 guidance – which appears increasingly achievable as improved GtN’s offset softening PCP Rxs." (8/4/2016)
Brean Capital analysts commented, "We valued Mallinckrodt via discounted cash flow analysis. We assigned the company an 11% weighted average cost of capital, since we view its commercial risk as manageable. We utilize a 2% terminal growth rate since the company has durable assets and is investing further in its pipeline." (8/2/2016)
Who owns Horizon Pharma PLC stock?
Horizon Pharma PLC's stock is owned by many different of institutional and retail investors. Top institutional investors include Deerfield Management Co. (5.55%), FMR LLC (3.54%), State Street Corp (2.69%), Janus Capital Management LLC (2.29%), Dimensional Fund Advisors LP (1.61%) and Hodges Capital Management Inc. (1.35%). Company insiders that own Horizon Pharma PLC stock include Jeff Himawan, Jeffrey W Sherman and Virinder Nohria.
Who sold Horizon Pharma PLC stock? Who is selling Horizon Pharma PLC stock?
Horizon Pharma PLC's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Fiera Capital Corp, Oxford Asset Management, Franklin Resources Inc., Janus Capital Management LLC, TCW Group Inc., Guggenheim Capital LLC and AQR Capital Management LLC. Company insiders that have sold Horizon Pharma PLC stock in the last year include Jeffrey W Sherman and Virinder Nohria.
Who bought Horizon Pharma PLC stock? Who is buying Horizon Pharma PLC stock?
Horizon Pharma PLC's stock was acquired by a variety of institutional investors in the last quarter, including Deerfield Management Co., Armistice Capital LLC, Dimensional Fund Advisors LP, Artal Group S.A., Systematic Financial Management LP, Russell Investments Group Ltd., State Street Corp and Seven Eight Capital LP.
How do I buy Horizon Pharma PLC stock?
Shares of Horizon Pharma PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Horizon Pharma PLC stock cost?
One share of Horizon Pharma PLC stock can currently be purchased for approximately $17.45.